RISERS
Kohl's (NYSE:KSS) rose 6.5% to $45.94 after the department store operator reported better-than-expected quarterly net sales and profit, helped by strong back-to-school sales.
Chembio Diagnostics (NASDAQ:CEMI) advanced 1.7% to $5.35 after the provider of rapid point-of-care diagnostic tests reported a narrower-than-expected quarterly loss and higher-than-estimated revenue.
Cynapsus Therapeutics (NASDAQ:CYNA) added 0.7% to $15.15, reversing an earlier slump. The developer of the APL-130277 drug for treating Parkinson's disease reported cash improved to $109.5mln as of September 30 from $17.4mln as of last December 30.
Regen BioPharma (OTCBB:RGBP) gained 15% to $0.155. The biotechnology company started preclinical studies evaluating utilization of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients with Dr. Santosh Kesari, professor of Neurosciences, at the John Wayne Cancer Institute.
Gogo (NASDAQ:GOGO) fluctuated and was last up 0.6% at $16.22. The provider of broadband connectivity solutions and wireless entertainment to the aviation industry unveiled its next generation satellite technology on Thursday during a series of flights on its Boeing 737 aircraft. The technology – called 2Ku – is expected to be launched commercially in the coming months.
FALLERS
Energizer (NYSE:ENR) slumped 11% to $35.44 after the battery maker lagged behind estimates by a penny with adjusted quarterly profit of $0.61 per share.
SinglePoint (OTCMKTS:SING) fell 17% to $0.00624. The full-service mobile technology and marketing provider said it has fully executed its agreement to acquire Text2Bid for $1.25mln.
Cancer test developer VolitionRx (NYSE:VNRX) revealed that chief executive Cameron Reynolds will be at two conferences this month to discuss the business's progress. The shares fell 6.1% to $4.00.